NEW DATA AT AHA 2026 DEMONSTRATES THE VALUE OF TREATMENT WITH REPATHA® EARLIER IN THE CARDIOVASCULAR RISK CONTINUUM - Amgen
NEW DATA AT AHA 2026 DEMONSTRATES THE VALUE OF TREATMENT WITH REPATHA® EARLIER IN THE CARDIOVASCULAR RISK CONTINUUM Amgen
Amgen Company News
FDA Approval for KANJINTI issued to AMGEN INC - Quantisnow
FDA Approval for KANJINTI issued to AMGEN INC Quantisnow
Amgen vs. Regeneron: Higher Dividends Now or Bigger Growth Later? - 24/7 Wall St.
Amgen vs. Regeneron: Higher Dividends Now or Bigger Growth Later? 24/7 Wall St.
Explosive Options' Bob Lang on why he likes Amgen - CNBC
Explosive Options' Bob Lang on why he likes Amgen CNBC
Amgen vs. Regeneron: Higher Dividends Now or Bigger Growth Later? - Yahoo Finance
Amgen vs. Regeneron: Higher Dividends Now or Bigger Growth Later? Yahoo Finance
Amgen Inc. stock rises Monday, still underperforms market - MarketWatch
Amgen Inc. stock rises Monday, still underperforms market MarketWatch
Amgen posts higher-than-expected third quarter results, but shares dip - Reuters
Amgen posts higher-than-expected third quarter results, but shares dip Reuters
Therapeutic Immune Manipulation - Genetic Engineering and Biotechnology News
Therapeutic Immune Manipulation Genetic Engineering and Biotechnology News
Amgen starts MariTide autoinjector study as pivotal readouts approach - BioSpace
Amgen starts MariTide autoinjector study as pivotal readouts approach BioSpace
Amgen (AMGN) Highlights Cost-Effectiveness of Repatha in New Car - GuruFocus
Amgen (AMGN) Highlights Cost-Effectiveness of Repatha in New Car GuruFocus
Amgen’s new drug could mean fewer shots for obesity patients - TheStreet
Amgen’s new drug could mean fewer shots for obesity patients TheStreet
Amgen’s Repatha linked to fewer heart attacks - STAT
Amgen’s Repatha linked to fewer heart attacks STAT
Amgen Inc. $AMGN Shares Sold by M&G PLC - MarketBeat
Amgen Inc. $AMGN Shares Sold by M&G PLC MarketBeat
AMGEN REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS - Amgen
AMGEN REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS Amgen
3 Biotech Stocks That Actually Pay Dividends and Keep Raising Them - 24/7 Wall St.
3 Biotech Stocks That Actually Pay Dividends and Keep Raising Them 24/7 Wall St.
REPATHA® LOWERS RISK OF HEART ATTACKS BY 20% COMPARED WITH EZETIMIBE IN A LARGE REAL-WORLD STUDY - Amgen
REPATHA® LOWERS RISK OF HEART ATTACKS BY 20% COMPARED WITH EZETIMIBE IN A LARGE REAL-WORLD STUDY Amgen
Amgen’s Dividend Has Grown 800% Since 2011. Here’s What It Pays Today - 24/7 Wall St.
Amgen’s Dividend Has Grown 800% Since 2011. Here’s What It Pays Today 24/7 Wall St.
Highlights from Amgen's 2026 Third Quarter Earnings Report - Amgen
Highlights from Amgen's 2026 Third Quarter Earnings Report Amgen
Amgen Ranks #4 on Forbes’ Most Innovative Large Companies List - Amgen
Amgen Ranks #4 on Forbes’ Most Innovative Large Companies List Amgen
Amgen touts Repatha's heart benefits in real-world comparison with ezetimibe - FirstWord Pharma
Amgen touts Repatha's heart benefits in real-world comparison with ezetimibe FirstWord Pharma
Amgen Inc. $AMGN Shares Sold by StoneX Group Inc. - MarketBeat
Amgen Inc. $AMGN Shares Sold by StoneX Group Inc. MarketBeat
Indices Hunt for Support After Steep Weekly Losses as Volatility Gauge Stays Elevated - Quantisnow
Indices Hunt for Support After Steep Weekly Losses as Volatility Gauge Stays Elevated Quantisnow
Amgen Inc Stock (AMGN) Closed Down by 3.80% on Nov 5: What Investors Need To Know - TradingKey
Amgen Inc Stock (AMGN) Closed Down by 3.80% on Nov 5: What Investors Need To Know TradingKey
Amgen Inc. $AMGN Shares Sold by Beutel Goodman & Co Ltd. - MarketBeat
Amgen Inc. $AMGN Shares Sold by Beutel Goodman & Co Ltd. MarketBeat
Amgen Inc. Q3 2026 Earnings Call Summary - Yahoo Finance
Amgen Inc. Q3 2026 Earnings Call Summary Yahoo Finance
3,429 Shares in Amgen Inc. $AMGN Acquired by M Holdings Securities Inc. - MarketBeat
3,429 Shares in Amgen Inc. $AMGN Acquired by M Holdings Securities Inc. MarketBeat
Rare Disease Treatment Patents after Amgen: Can Claims Cover Untested Genetic Mutations? - IPWatchdog
Rare Disease Treatment Patents after Amgen: Can Claims Cover Untested Genetic Mutations? IPWatchdog
Amgen Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Amgen Inc. stock underperforms Thursday when compared to competitors MarketWatch
AMGEN TO PRESENT AT THE MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCE - Amgen
AMGEN TO PRESENT AT THE MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCE Amgen
Amgen Raises Forecasts Again as Sales Top Expectations - Bloomberg.com
Amgen Raises Forecasts Again as Sales Top Expectations Bloomberg.com
Amgen's MariTide Aims to Cut Obesity Shots From 52 a Year to as Few as Four - BigGo Finance
Amgen's MariTide Aims to Cut Obesity Shots From 52 a Year to as Few as Four BigGo Finance
Amgen Named Among World’s Most Impactful Companies 2026 by TIME - Amgen
Amgen Named Among World’s Most Impactful Companies 2026 by TIME Amgen
Amgen Analyst Likes Diversified Business, Remains Patient Until MariTide Obesity Data - Benzinga
Amgen Analyst Likes Diversified Business, Remains Patient Until MariTide Obesity Data Benzinga
Form 4 Amgen Inc: Michael V. Drake (Director) For: 6 November - Investing.com Canada
Form 4 Amgen Inc: Michael V. Drake (Director) For: 6 November Investing.com Canada
Amgen's quality chief to retire as internal successor steps up - Fierce Pharma
Amgen's quality chief to retire as internal successor steps up Fierce Pharma
Amgen Inc (AMGN) Shares Fall 3.8% -- GF Value Says Still Overval - GuruFocus
Amgen Inc (AMGN) Shares Fall 3.8% -- GF Value Says Still Overval GuruFocus
Satellos’ new Duchenne study endpoint; Amgen’s Repatha cuts heart attack risk - Endpoints News
Satellos’ new Duchenne study endpoint; Amgen’s Repatha cuts heart attack risk Endpoints News
Amgen CEO Bob Bradway's 2025 Letter to Shareholders - Amgen
Amgen CEO Bob Bradway's 2025 Letter to Shareholders Amgen
Amgen’s Repatha shows cost-effectiveness in cardiovascular study - Yahoo Finance
Amgen’s Repatha shows cost-effectiveness in cardiovascular study Yahoo Finance
Form 4 Amgen Inc: David W. Gibbs (Director) For: 6 November By Investing.com - Investing.com India
Form 4 Amgen Inc: David W. Gibbs (Director) For: 6 November By Investing.com Investing.com India